Cancel
Known information
- Has been innovating in women's health for over 20 years
- Completed PhD work at Cornell (Weill, NYC) and Memorial Sloan Kettering Cancer Center
- Focused on precision medicine in oncology during PhD
- Completed a post-doc focused on mammalian reproduction at the University of Cambridge (UK)
- Pioneered breakthroughs in decoding the genomic drivers of ovarian function and health
- Primary inventor of Celmatix’s innovations, including the AMHR2 agonist and antagonist programs
- Developed diagnostics and digital health products in the women’s health field
- Member of the Aspen Global Leadership Network
- Named to Crain’s 40 Under 40 and Notable Women in Tech
- Recognized by Goldman Sachs as one of the Most Intriguing Entrepreneurs
- Listed among Top 15 founders disrupting their industries by Fortune
- Received Rock Health's Disruptive Founder of the Year award
About Celmatix
Celmatix is a preclinical-stage biotech company dedicated to improving women's health by focusing on ovarian health, leveraging the world's largest structured dataset on ovarian health and outcomes.
Report inaccurate information
